SARS-CoV-2 (COVID-19) by GeneTex



With SARS-CoV-2 now reaching pandemic status, researchers and clinicians have been working furiously to learn more about the virus’s biology and pathogenesis as well as how to treat the more clinically aggressive COVID-19 cases. As with any viral pathogen, understanding how SARS-CoV-2 enters host cells is of great significance.

In their study published very recently in Cell, Hoffmann et al. confirm findings reported by Zhou et al. that angiotensin-converting enzyme 2 (ACE2) is the cellular receptor for SARS-CoV-2, as it is for SARS-CoV (2, 3). In addition, they identify the serine protease TMPRSS2 as a critical factor in the priming of the SARS-CoV-2 spike (S) protein, an essential step for viral entry into host cells through fusion of the viral and cellular membranes. The authors also demonstrate that the serine protease inhibitor camostat mesylate, an agent that has already seen clinical application as a treatment for chronic pancreatitis in Japan, is able to interfere with SARS-CoV-2 infection of lung cells. Finally, the study presents data that antibodies generated to SARS-CoV S protein may have some protective activity against SARS-CoV-2. Together, this work expands our knowledge of key factors involved in SARS-CoV-2’s entry into cells and reveals some promising avenues for SARS-CoV-2-directed therapies.

GeneTex offers an extensive line of research antibodies and proteins to support the study of SARS-CoV-2, several of which were validated using virus-infected cell lysates.


 
 
 
SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9] (GTX632604)
 SARS-CoV / SARS-CoV-2 (COVID-19) nucleocapsid antibody [6H3] (GTX632269)
 SARS-CoV-2 (COVID-19) nucleocapsid protein (GTX135357-pro)
 Human ACE2 protein (active) (GTX01179-pro)

Products to support the study of SARS-CoV-2


Cat. No.DescriptionHostClonalityApplication
GTX135357SARS-CoV-2 (COVID-19) nucleocapsid antibodyRabbitPolyclonalWB, ICC/IF
GTX135356SARS-CoV-2 (COVID-19) spike antibodyRabbitPolyclonalWB, ICC/IF
GTX135357-proSARS-CoV-2 (COVID-19) nucleocapsid protein


GTX15349ACE2 antibodyRabbitPolyclonalWB, ICC/IF, IHC-P, ELISA
GTX31680ACE2 antibodyRabbitPolyclonalWB, IHC-P, ELISA
GTX52524ACE2 antibody [11A31]MouseMonoclonalWB, IHC-P
GTX101395ACE2 antibody [N1N2], N-termMouseMonoclonalIHC-P, WB
GTX01160ACE2 antibody [SN0754]RabbitMonoclonalWB, ICC/IF, IHC-P
GTX632604SARS-CoV / SARS-CoV-2 (COVID-19) spike antibody [1A9]MouseMonoclonalWB, FACS
GTX632602SARS-CoV 7a protein antibody [3C9]MouseMonoclonalWB, ICC/IF
GTX632696SARS-CoV NS8 antibody [5A10]MouseMonoclonalWB
GTX632269SARS-CoV Nucleocapsid antibody [6H3]MouseMonoclonalWB, ICC/IF
GTX15354ACE2 peptide (169-183)

Neutralizing/Blocking
GTX15351ACE2 peptide (192-208)

Neutralizing/Blocking
GTX15353ACE2 peptide (2-18)

Neutralizing/Blocking
GTX15352ACE2 peptide (788-805)

Control, Neutralizing/Blocking
GTX01179-proHuman ACE2 protein (active)

Functional Assay
GTX100743
TMPRSS2 antibody [N2C3]
Rabbit
Polyclonal
WB

References:

  1. Nature News. 11 March 2020.
  2. Zhou et al. Nature 579, 270-273 (2020).
  3. Hoffmann et al. Cell 181, 1-10 (2020).

More COVID-19 reagents »»